Oncology

A landmark study validates Astrin Biosciences' proteomic test, Certitude, boasting >92% accuracy and offering new hope for women with dense breasts.

As Cellectar Biosciences preps its Q2 report, all eyes are on its cash runway and the immense promise of its targeted cancer therapy platform.

The LUNGevity Foundation joins the world's largest marathon, a strategic play to amplify fundraising and confront the stark realities of a misunderstood disease.

With FDA clearance for IKS04, Iksuda Therapeutics unveils a novel co-dosing strategy to deliver a potent payload past notorious tumor barriers.

A new AI model is mining millions of patient notes for cancer data once thought inaccessible, promising to accelerate research and transform patient care.

A new $18.7M initiative isn't just a health campaign; it's a calculated investment to reverse Oklahoma's dire health stats and boost its economic future.

A new initiative empowers cancer survivors to become advocates, tackling the silent crisis of oncofertility and forcing a systemic shift in patient care.

Lantern Pharma's EMA-cleared trial for LP-184 uses a dual-biomarker strategy, targeting a multi-billion dollar market where patient options are scarce.

A new biotech, CORE Biomedicine, armed with Eisai's preclinical assets and a $21M Series A, aims to upend oncology by targeting cancer's 'lineage' identity.

With $21M in funding and a novel 'lineage-based' approach, CORE Biomedicine is moving beyond genomics to target the root cause of cancer's identity.

With two blockbuster cancer drugs driving revenue, Syndax's upcoming Q2 report is a critical test of its path to profitability and ambitious pipeline.

On World Lung Cancer Day, a $400,000 investment isn't just funding research; it's backing a new generation of scientists tackling the disease's biggest challenges.

A prestigious oncology award is more than a personal accolade. It’s a signal of a shrewd strategy by regional players like Baystate Health to shape the future of medicine from the inside out.

A Yale symposium reveals a new economic force: patient advocacy groups are directing capital and innovation in the fight against complex diseases.

SOHO's new 'Spotlight' podcast isn't just another show; it's a strategic move to bring cutting-edge cancer research directly to clinicians.

New trial data shows an incision-free therapy preserves patient quality of life, challenging the long-held dominance of robotic surgery in prostate cancer.

Radiopharm Theranostics secures crucial funding for its promising oncology pipeline, but a sharp stock drop reveals deep investor concerns about dilution.

Samsung Epis Holdings reports solid growth driven by its biosimilar portfolio, but the real story is its strategic pivot to next-gen cancer drugs and global expansion.

A landmark study in Nature unveils a novel 'armored' cell therapy that neutralizes tumor defenses, showing remarkable efficacy in advanced liver cancer.

With a mixed Q1 and a promise of a stronger second half, Myriad Genetics' upcoming earnings call will be a crucial test of its strategic health and pipeline.